Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 265 to 276 of 276 entries
Sorted by: Best Match Show Resources per page
Characterizing the COVID-19 illness experience to inform the study of post-acute sequelae and recovery: a qualitative study.

medRxiv : the preprint server for health sciences

Santiago-Rodriguez EI, Maiorana A, Peluso MJ, Hoh R, Tai V, Fehrman EA, Hernandez Y, Torres L, Spinelli MA, Gandhi M, Kelly JD, Martin JN, Henrich TJ, Deeks SG, Sauceda JA.
PMID: 33758881
medRxiv. 2021 Mar 24; doi: 10.1101/2021.03.10.21253330.

We aimed to characterize the variability in the illness experience and recovery process from COVID-19. We conducted in-depth individual interviews with participants enrolled in the Long-term Immunological Impact of Novel Coronavirus (LIINC) cohort study in San Francisco, California from...

Cite
Santiago-Rodriguez EI, Maiorana A, Peluso MJ, et al. Characterizing the COVID-19 illness experience to inform the study of post-acute sequelae and recovery: a qualitative study. medRxiv. 2021;doi: 10.1101/2021.03.10.21253330.
Santiago-Rodriguez, E. I., Maiorana, A., Peluso, M. J., Hoh, R., Tai, V., Fehrman, E. A., Hernandez, Y., Torres, L., Spinelli, M. A., Gandhi, M., Kelly, J. D., Martin, J. N., Henrich, T. J., Deeks, S. G., & Sauceda, J. A. (2021). Characterizing the COVID-19 illness experience to inform the study of post-acute sequelae and recovery: a qualitative study. medRxiv : the preprint server for health sciences, . https://doi.org/10.1101/2021.03.10.21253330
Santiago-Rodriguez, Edda I, et al. "Characterizing the COVID-19 illness experience to inform the study of post-acute sequelae and recovery: a qualitative study." medRxiv : the preprint server for health sciences vol. (2021). doi: https://doi.org/10.1101/2021.03.10.21253330
Santiago-Rodriguez EI, Maiorana A, Peluso MJ, Hoh R, Tai V, Fehrman EA, Hernandez Y, Torres L, Spinelli MA, Gandhi M, Kelly JD, Martin JN, Henrich TJ, Deeks SG, Sauceda JA. Characterizing the COVID-19 illness experience to inform the study of post-acute sequelae and recovery: a qualitative study. medRxiv. 2021 Mar 24; doi: 10.1101/2021.03.10.21253330. PMID: 33758881; PMCID: PMC7987040.
Copy Download .nbib Format: NLM
HIV-1 Genomes Are Enriched in Memory CD4.

mBio

Morcilla V, Bacchus-Souffan C, Fisher K, Horsburgh BA, Hiener B, Wang XQ, Schlub TE, Fitch M, Hoh R, Hecht FM, Martin JN, Deeks SG, Hellerstein MK, McCune JM, Hunt PW, Palmer S.
PMID: 34544282
mBio. 2021 Oct 26;12(5):e0244721. doi: 10.1128/mBio.02447-21. Epub 2021 Sep 21.

Future HIV-1 curative therapies require a thorough understanding of the distribution of genetically-intact HIV-1 within T-cell subsets during antiretroviral therapy (ART) and the cellular mechanisms that maintain this reservoir. Therefore, we sequenced near-full-length HIV-1 genomes and identified genetically-intact and...

Cite
Morcilla V, Bacchus-Souffan C, Fisher K, et al. HIV-1 Genomes Are Enriched in Memory CD4. mBio. 2021;12(5):e0244721doi: 10.1128/mBio.02447-21.
Morcilla, V., Bacchus-Souffan, C., Fisher, K., Horsburgh, B. A., Hiener, B., Wang, X. Q., Schlub, T. E., Fitch, M., Hoh, R., Hecht, F. M., Martin, J. N., Deeks, S. G., Hellerstein, M. K., McCune, J. M., Hunt, P. W., & Palmer, S. (2021). HIV-1 Genomes Are Enriched in Memory CD4. mBio, 12(5), e0244721. https://doi.org/10.1128/mBio.02447-21
Morcilla, Vincent, et al. "HIV-1 Genomes Are Enriched in Memory CD4." mBio vol. 12,5 (2021): e0244721. doi: https://doi.org/10.1128/mBio.02447-21
Morcilla V, Bacchus-Souffan C, Fisher K, Horsburgh BA, Hiener B, Wang XQ, Schlub TE, Fitch M, Hoh R, Hecht FM, Martin JN, Deeks SG, Hellerstein MK, McCune JM, Hunt PW, Palmer S. HIV-1 Genomes Are Enriched in Memory CD4. mBio. 2021 Oct 26;12(5):e0244721. doi: 10.1128/mBio.02447-21. Epub 2021 Sep 21. PMID: 34544282; PMCID: PMC8546577.
Copy Download .nbib Format: NLM
Accumulation of HIV-1 Drug Resistance Mutations and Methamphetamine Use.

Current HIV research

Truong HM, Fatch R, Deeks SG, Krone M, Martin JN, Hunt PW, Lum PJ.
PMID: 34176462
Curr HIV Res. 2021 Jun 24; doi: 10.2174/1570162X19666210625103902. Epub 2021 Jun 24.

BACKGROUND: Antiretroviral therapy (ART) non-adherence and methamphetamine use are associated with higher HIV drug resistance prevalence. How they affect drug resistance mutation accumulation is less studied.OBJECTIVE: We assessed factors associated with drug resistance mutation accumulation.METHODS: We evaluated HIV chronically-infected...

Cite
Truong HM, Fatch R, Deeks SG, et al. Accumulation of HIV-1 Drug Resistance Mutations and Methamphetamine Use. Curr HIV Res. 2021;doi: 10.2174/1570162X19666210625103902.
Truong, H. M., Fatch, R., Deeks, S. G., Krone, M., Martin, J. N., Hunt, P. W., & Lum, P. J. (2021). Accumulation of HIV-1 Drug Resistance Mutations and Methamphetamine Use. Current HIV research, . https://doi.org/10.2174/1570162X19666210625103902
Truong, Hong-Ha M, et al. "Accumulation of HIV-1 Drug Resistance Mutations and Methamphetamine Use." Current HIV research vol. (2021). doi: https://doi.org/10.2174/1570162X19666210625103902
Truong HM, Fatch R, Deeks SG, Krone M, Martin JN, Hunt PW, Lum PJ. Accumulation of HIV-1 Drug Resistance Mutations and Methamphetamine Use. Curr HIV Res. 2021 Jun 24; doi: 10.2174/1570162X19666210625103902. Epub 2021 Jun 24. PMID: 34176462.
Copy Download .nbib Format: NLM
Belzutifan: First Approval.

Drugs

Deeks ED.
PMID: 34613603
Drugs. 2021 Nov;81(16):1921-1927. doi: 10.1007/s40265-021-01606-x.

Belzutifan (Welireg™) is an oral small molecule inhibitor of hypoxia-inducible factor (HIF)-2α being developed by Peloton Therapeutics for the treatment of solid tumours, including renal cell carcinoma (RCC) with clear cell histology (ccRCC) and von Hippel-Lindau (VHL) disease-associated RCC....

Cite
Deeks ED. Belzutifan: First Approval. Drugs. 2021;81(16):1921-1927doi: 10.1007/s40265-021-01606-x.
Deeks, E. D. (2021). Belzutifan: First Approval. Drugs, 81(16), 1921-1927. https://doi.org/10.1007/s40265-021-01606-x
Deeks, Emma D. "Belzutifan: First Approval." Drugs vol. 81,16 (2021): 1921-1927. doi: https://doi.org/10.1007/s40265-021-01606-x
Deeks ED. Belzutifan: First Approval. Drugs. 2021 Nov;81(16):1921-1927. doi: 10.1007/s40265-021-01606-x. PMID: 34613603.
Copy Download .nbib Format: NLM
Furmonertinib: First Approval.

Drugs

Deeks ED.
PMID: 34528187
Drugs. 2021 Oct;81(15):1775-1780. doi: 10.1007/s40265-021-01588-w.

Furmonertinib mesylate (hereafter furmonertinib) [Ivesa

Cite
Deeks ED. Furmonertinib: First Approval. Drugs. 2021;81(15):1775-1780doi: 10.1007/s40265-021-01588-w.
Deeks, E. D. (2021). Furmonertinib: First Approval. Drugs, 81(15), 1775-1780. https://doi.org/10.1007/s40265-021-01588-w
Deeks, Emma D. "Furmonertinib: First Approval." Drugs vol. 81,15 (2021): 1775-1780. doi: https://doi.org/10.1007/s40265-021-01588-w
Deeks ED. Furmonertinib: First Approval. Drugs. 2021 Oct;81(15):1775-1780. doi: 10.1007/s40265-021-01588-w. PMID: 34528187.
Copy Download .nbib Format: NLM
Accumulation of HIV-1 Drug Resistance Mutations and Methamphetamine Use.

Current HIV research

Truong HM, Fatch R, Deeks SG, Krone M, Martin JN, Hunt PW, Lum PJ.
PMID: 34176462
Curr HIV Res. 2021 Jun 24; doi: 10.2174/1570162X19666210625103902. Epub 2021 Jun 24.

BACKGROUND: Antiretroviral therapy (ART) non-adherence and methamphetamine use are associated with higher HIV drug resistance prevalence. How they affect drug resistance mutation accumulation is less studied.OBJECTIVE: We assessed factors associated with drug resistance mutation accumulation.METHODS: We evaluated HIV chronically-infected...

Cite
Truong HM, Fatch R, Deeks SG, et al. Accumulation of HIV-1 Drug Resistance Mutations and Methamphetamine Use. Curr HIV Res. 2021;doi: 10.2174/1570162X19666210625103902.
Truong, H. M., Fatch, R., Deeks, S. G., Krone, M., Martin, J. N., Hunt, P. W., & Lum, P. J. (2021). Accumulation of HIV-1 Drug Resistance Mutations and Methamphetamine Use. Current HIV research, . https://doi.org/10.2174/1570162X19666210625103902
Truong, Hong-Ha M, et al. "Accumulation of HIV-1 Drug Resistance Mutations and Methamphetamine Use." Current HIV research vol. (2021). doi: https://doi.org/10.2174/1570162X19666210625103902
Truong HM, Fatch R, Deeks SG, Krone M, Martin JN, Hunt PW, Lum PJ. Accumulation of HIV-1 Drug Resistance Mutations and Methamphetamine Use. Curr HIV Res. 2021 Jun 24; doi: 10.2174/1570162X19666210625103902. Epub 2021 Jun 24. PMID: 34176462.
Copy Download .nbib Format: NLM
Assessment of population infection with SARS-CoV-2 in Ontario, Canada, March to June 2020.

Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin

Bolotin S, Tran V, Deeks SL, Peci A, Brown KA, Buchan SA, Ogbulafor K, Ramoutar T, Nguyen M, Thakkar R, DelaCruz R, Mustfa R, Maregmen J, Woods O, Krasna T, Cronin K, Osman S, Joh E, Allen VG.
PMID: 34915969
Euro Surveill. 2021 Dec;26(50). doi: 10.2807/1560-7917.ES.2021.26.50.2001559.

BackgroundSerosurveys for SARS-CoV-2 aim to estimate the proportion of the population that has been infected.AimThis observational study assesses the seroprevalence of SARS-CoV-2 antibodies in Ontario, Canada during the first pandemic wave.MethodsUsing an orthogonal approach, we tested 8,902 residual specimens...

Cite
Bolotin S, Tran V, Deeks SL, et al. Assessment of population infection with SARS-CoV-2 in Ontario, Canada, March to June 2020. Euro Surveill. 2021;26(50)doi: 10.2807/1560-7917.ES.2021.26.50.2001559.
Bolotin, S., Tran, V., Deeks, S. L., Peci, A., Brown, K. A., Buchan, S. A., Ogbulafor, K., Ramoutar, T., Nguyen, M., Thakkar, R., DelaCruz, R., Mustfa, R., Maregmen, J., Woods, O., Krasna, T., Cronin, K., Osman, S., Joh, E., & Allen, V. G. (2021). Assessment of population infection with SARS-CoV-2 in Ontario, Canada, March to June 2020. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 26(50), . https://doi.org/10.2807/1560-7917.ES.2021.26.50.2001559
Bolotin, Shelly, et al. "Assessment of population infection with SARS-CoV-2 in Ontario, Canada, March to June 2020." Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin vol. 26,50 (2021). doi: https://doi.org/10.2807/1560-7917.ES.2021.26.50.2001559
Bolotin S, Tran V, Deeks SL, Peci A, Brown KA, Buchan SA, Ogbulafor K, Ramoutar T, Nguyen M, Thakkar R, DelaCruz R, Mustfa R, Maregmen J, Woods O, Krasna T, Cronin K, Osman S, Joh E, Allen VG. Assessment of population infection with SARS-CoV-2 in Ontario, Canada, March to June 2020. Euro Surveill. 2021 Dec;26(50). doi: 10.2807/1560-7917.ES.2021.26.50.2001559. PMID: 34915969.
Copy Download .nbib Format: NLM
Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021.

Nature medicine

Deeks SG, Archin N, Cannon P, Collins S, Jones RB, de Jong MAWP, Lambotte O, Lamplough R, Ndung'u T, Sugarman J, Tiemessen CT, Vandekerckhove L, Lewin SR.
PMID: 34848888
Nat Med. 2021 Dec 01; doi: 10.1038/s41591-021-01590-5. Epub 2021 Dec 01.

Despite the success of antiretroviral therapy (ART) for people living with HIV, lifelong treatment is required and there is no cure. HIV can integrate in the host genome and persist for the life span of the infected cell. These...

Cite
Deeks SG, Archin N, Cannon P, et al. Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021. Nat Med. 2021;doi: 10.1038/s41591-021-01590-5.
Deeks, S. G., Archin, N., Cannon, P., Collins, S., Jones, R. B., de Jong, M. A. W. P., Lambotte, O., Lamplough, R., Ndung'u, T., Sugarman, J., Tiemessen, C. T., Vandekerckhove, L., Lewin, S. R. (2021). Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021. Nature medicine, . https://doi.org/10.1038/s41591-021-01590-5
Deeks, Steven G, et al. "Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021." Nature medicine vol. (2021). doi: https://doi.org/10.1038/s41591-021-01590-5
Deeks SG, Archin N, Cannon P, Collins S, Jones RB, de Jong MAWP, Lambotte O, Lamplough R, Ndung'u T, Sugarman J, Tiemessen CT, Vandekerckhove L, Lewin SR. Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021. Nat Med. 2021 Dec 01; doi: 10.1038/s41591-021-01590-5. Epub 2021 Dec 01. PMID: 34848888.
Copy Download .nbib Format: NLM
QUADAS-C: A Tool for Assessing Risk of Bias in Comparative Diagnostic Accuracy Studies.

Annals of internal medicine

Yang B, Mallett S, Takwoingi Y, Davenport CF, Hyde CJ, Whiting PF, Deeks JJ, Leeflang MMG.
PMID: 34698503
Ann Intern Med. 2021 Nov;174(11):1592-1599. doi: 10.7326/M21-2234. Epub 2021 Oct 26.

Comparative diagnostic test accuracy studies assess and compare the accuracy of 2 or more tests in the same study. Although these studies have the potential to yield reliable evidence regarding comparative accuracy, shortcomings in the design, conduct, and analysis...

Cite
Yang B, Mallett S, Takwoingi Y, et al. QUADAS-C: A Tool for Assessing Risk of Bias in Comparative Diagnostic Accuracy Studies. Ann Intern Med. 2021;174(11):1592-1599doi: 10.7326/M21-2234.
Yang, B., Mallett, S., Takwoingi, Y., Davenport, C. F., Hyde, C. J., Whiting, P. F., Deeks, J. J., Leeflang, M. M. G. (2021). QUADAS-C: A Tool for Assessing Risk of Bias in Comparative Diagnostic Accuracy Studies. Annals of internal medicine, 174(11), 1592-1599. https://doi.org/10.7326/M21-2234
Yang, Bada, et al. "QUADAS-C: A Tool for Assessing Risk of Bias in Comparative Diagnostic Accuracy Studies." Annals of internal medicine vol. 174,11 (2021): 1592-1599. doi: https://doi.org/10.7326/M21-2234
Yang B, Mallett S, Takwoingi Y, Davenport CF, Hyde CJ, Whiting PF, Deeks JJ, Leeflang MMG. QUADAS-C: A Tool for Assessing Risk of Bias in Comparative Diagnostic Accuracy Studies. Ann Intern Med. 2021 Nov;174(11):1592-1599. doi: 10.7326/M21-2234. Epub 2021 Oct 26. PMID: 34698503.
Copy Download .nbib Format: NLM
Discordant Virus-Specific Antibody Levels, Antibody Neutralization Capacity, and T-cell Responses Following 3 Doses of SARS-CoV-2 Vaccination in a Patient With Connective Tissue Disease.

Open forum infectious diseases

Peluso MJ, Munter SE, Lynch KL, Yun C, Torres L, Iyer NS, Donatelli J, Ryan L, Deitchman AN, Deeks SG, Rutishauser RL, Henrich TJ.
PMID: 34395717
Open Forum Infect Dis. 2021 Jul 29;8(8):ofab393. doi: 10.1093/ofid/ofab393. eCollection 2021 Aug.

We report a patient with connective tissue disease who developed modest severe acute respiratory syndrome coronavirus 2 receptor binding domain-specific antibody levels and a lack of neutralization capacity, despite having received 3 mRNA coronavirus disease 2019 vaccines and holding...

Cite
Peluso MJ, Munter SE, Lynch KL, et al. Discordant Virus-Specific Antibody Levels, Antibody Neutralization Capacity, and T-cell Responses Following 3 Doses of SARS-CoV-2 Vaccination in a Patient With Connective Tissue Disease. Open Forum Infect Dis. 2021;8(8):ofab393doi: 10.1093/ofid/ofab393.
Peluso, M. J., Munter, S. E., Lynch, K. L., Yun, C., Torres, L., Iyer, N. S., Donatelli, J., Ryan, L., Deitchman, A. N., Deeks, S. G., Rutishauser, R. L., & Henrich, T. J. (2021). Discordant Virus-Specific Antibody Levels, Antibody Neutralization Capacity, and T-cell Responses Following 3 Doses of SARS-CoV-2 Vaccination in a Patient With Connective Tissue Disease. Open forum infectious diseases, 8(8), ofab393. https://doi.org/10.1093/ofid/ofab393
Peluso, Michael J, et al. "Discordant Virus-Specific Antibody Levels, Antibody Neutralization Capacity, and T-cell Responses Following 3 Doses of SARS-CoV-2 Vaccination in a Patient With Connective Tissue Disease." Open forum infectious diseases vol. 8,8 (2021): ofab393. doi: https://doi.org/10.1093/ofid/ofab393
Peluso MJ, Munter SE, Lynch KL, Yun C, Torres L, Iyer NS, Donatelli J, Ryan L, Deitchman AN, Deeks SG, Rutishauser RL, Henrich TJ. Discordant Virus-Specific Antibody Levels, Antibody Neutralization Capacity, and T-cell Responses Following 3 Doses of SARS-CoV-2 Vaccination in a Patient With Connective Tissue Disease. Open Forum Infect Dis. 2021 Jul 29;8(8):ofab393. doi: 10.1093/ofid/ofab393. eCollection 2021 Aug. PMID: 34395717; PMCID: PMC8344490.
Copy Download .nbib Format: NLM
Letter to the Editor regarding Peto T; UK COVID-19 Lateral Flow Oversight Team: COVID-19: Rapid antigen detection for SARS-CoV-2 by lateral flow assay.

EClinicalMedicine

Deeks JJ, Dinnes J, Davenport C, Takwoingi Y, McInnes M, Leeflang MM, Cunningham J.
PMID: 34308323
EClinicalMedicine. 2021 Aug;38:101037. doi: 10.1016/j.eclinm.2021.101037. Epub 2021 Jul 15.

No abstract available.

Cite
Deeks JJ, Dinnes J, Davenport C, et al. Letter to the Editor regarding Peto T; UK COVID-19 Lateral Flow Oversight Team: COVID-19: Rapid antigen detection for SARS-CoV-2 by lateral flow assay. EClinicalMedicine. 2021;38:101037doi: 10.1016/j.eclinm.2021.101037.
Deeks, J. J., Dinnes, J., Davenport, C., Takwoingi, Y., McInnes, M., Leeflang, M. M., & Cunningham, J. (2021). Letter to the Editor regarding Peto T; UK COVID-19 Lateral Flow Oversight Team: COVID-19: Rapid antigen detection for SARS-CoV-2 by lateral flow assay. EClinicalMedicine, 38101037. https://doi.org/10.1016/j.eclinm.2021.101037
Deeks, Jonathan J, et al. "Letter to the Editor regarding Peto T; UK COVID-19 Lateral Flow Oversight Team: COVID-19: Rapid antigen detection for SARS-CoV-2 by lateral flow assay." EClinicalMedicine vol. 38 (2021): 101037. doi: https://doi.org/10.1016/j.eclinm.2021.101037
Deeks JJ, Dinnes J, Davenport C, Takwoingi Y, McInnes M, Leeflang MM, Cunningham J. Letter to the Editor regarding Peto T; UK COVID-19 Lateral Flow Oversight Team: COVID-19: Rapid antigen detection for SARS-CoV-2 by lateral flow assay. EClinicalMedicine. 2021 Aug;38:101037. doi: 10.1016/j.eclinm.2021.101037. Epub 2021 Jul 15. PMID: 34308323; PMCID: PMC8280129.
Copy Download .nbib Format: NLM
Rapamycin enhances BCG-specific γδ T cells during intravesical BCG therapy for non-muscle invasive bladder cancer: a randomized, double-blind study.

Journal for immunotherapy of cancer

Ji N, Mukherjee N, Reyes RM, Gelfond J, Javors M, Meeks JJ, McConkey DJ, Shu ZJ, Ramamurthy C, Dennett R, Curiel TJ, Svatek RS.
PMID: 33653802
J Immunother Cancer. 2021 Mar;9(3). doi: 10.1136/jitc-2020-001941.

BACKGROUND: Although intravesical BCG is the standard treatment of high-grade non-muscle invasive bladder cancer (NMIBC), response rates remain unsatisfactory. In preclinical models, rapamycin enhances BCG vaccine efficacy against tuberculosis and the killing capacity of γδ T cells, which are...

Cite
Ji N, Mukherjee N, Reyes RM, et al. Rapamycin enhances BCG-specific γδ T cells during intravesical BCG therapy for non-muscle invasive bladder cancer: a randomized, double-blind study. J Immunother Cancer. 2021;9(3)doi: 10.1136/jitc-2020-001941.
Ji, N., Mukherjee, N., Reyes, R. M., Gelfond, J., Javors, M., Meeks, J. J., McConkey, D. J., Shu, Z. J., Ramamurthy, C., Dennett, R., Curiel, T. J., & Svatek, R. S. (2021). Rapamycin enhances BCG-specific γδ T cells during intravesical BCG therapy for non-muscle invasive bladder cancer: a randomized, double-blind study. Journal for immunotherapy of cancer, 9(3), . https://doi.org/10.1136/jitc-2020-001941
Ji, Niannian, et al. "Rapamycin enhances BCG-specific γδ T cells during intravesical BCG therapy for non-muscle invasive bladder cancer: a randomized, double-blind study." Journal for immunotherapy of cancer vol. 9,3 (2021). doi: https://doi.org/10.1136/jitc-2020-001941
Ji N, Mukherjee N, Reyes RM, Gelfond J, Javors M, Meeks JJ, McConkey DJ, Shu ZJ, Ramamurthy C, Dennett R, Curiel TJ, Svatek RS. Rapamycin enhances BCG-specific γδ T cells during intravesical BCG therapy for non-muscle invasive bladder cancer: a randomized, double-blind study. J Immunother Cancer. 2021 Mar;9(3). doi: 10.1136/jitc-2020-001941. PMID: 33653802; PMCID: PMC7929866.
Copy Download .nbib Format: NLM
Showing 265 to 276 of 276 entries